Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Neratinib

Review the clinical trials studying neratinib on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-9 of 9

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Location: 34 locations
Abemaciclib, DNA-PK/TOR Kinase Inhibitor CC-115, Neratinib, or QBS10072S in Treating Patients with Brain Tumors after Biomarker Screening
Status: Active
Location: 6 locations
Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
Status: Active
Location: 3 locations
Neratinib and Trastuzumab Deruxtecan for the Treatment of HER2 Overexpressing Unresectable or Metastatic Gastrointestinal Cancer
Status: Active
Location: 3 locations
Neratinib Plus Capecitabine for the Treatment of Her2-Negative Metastatic Breast Cancer with Brain Metastases, FACT-5 Trial
Status: Active
Location: University of Rochester, Rochester, New York
Neoadjuvant Neratinib for the Treatment of Stage I-III HER2-Mutated Lobular Breast Cancers
Status: Active
Location: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Neratinib in Combination with Chemotherapy, Trastuzumab, Pembrolizumab in Patients with Stage HER2 Overexpressing Stage IV Gastroesophageal Cancers
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Fulvestrant and Neratinib, Alpelisib, Everolimus or Abemaciclib for the Treatment of Estrogen Receptor Positive HER2 Negative Metastatic or Locally Recurrent Breast Cancer Previously Treated with a CDK4/6 Inhibitor, GERTRUDE Trial
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers
Status: Active
Location: VCU Massey Comprehensive Cancer Center, Richmond, Virginia